Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-Hsct) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses